- You can view the full Threshold Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Threshold Pharma (THLD) stock is advancing on Monday afternoon alongside other biopharma stocks as fellow drug maker Medivation (MDVN) agreed to be bought by Pfizer (PFE) for $14 billion.
Data from CytRx's phase III study of aldoxorubicin for the treatment of patients with soft-tissue sarcoma are being analyzed right now, with results expected toward the end of June.
Trade-Ideas LLC identified Threshold Pharmaceuticals (THLD) as a weak on high relative volume candidate